Designed for trade association, exhibitors, academic institutions and speakers, List and promote your online events
Largest database of verified shows since 2015, Detailed profiles of verified trade shows, conferences and consumer shows. Create your event and attract attendees and exhibitiors, Listing tools for verification, institution and corporation.
Connect with verified event organizers, Listing and RFP tools for verified venue operators.Size events by verified attendee and exhibitor count database
Research verified b2b events by industry and profession, Review virtual exhibitor showcase. Create Profile. Connect with verified event organizers and exhibitors.
Search 900k verified exhibitor database organizedby 2,000+ events since 2018.
Overview:
The topic is 510(k) changes, a topic that is still producing more than its share of 483's and warning letters. In general, FDA does not return filings because the change described in them is not sufficiently "significant", and only rarely suggests that the traditional 510(k) should at least be scaled down to a special 510(k).
Therefore, it is up to the sponsor/manufacturer to determine whether this change will be significant or not. The decision has to be made by the manufacturer, subject to review by the FDA inspector. This talk will provide quality and regulatory personnel the means to help to the company make the right decision and document it fully, before the change goes through.
Why should you Attend: Failure to file a 510(k) for a change to a product which has already been cleared under 510(k) is one of the more frequent complaints in 483's and in warning letters. The result of this finding is the requirement to file a 510(k) for a product that is on the market, and usually, to file a 510(k) and have the change cleared before the product can be marketed with the change. In general, FDA will not insist on recalling product with the change already in the market unless they decide there is a safety issue, but even so, this means disruption of the manufacturing (already producing the changed product) and marketing for the product. The best approach is to understand what FDA means by a "significant change" and document completely the reasons why you believe the change does not warrant a filing.
Areas Covered in the Session:
Who Will Benefit:
Speaker Profile:
Anna Longwell is currently principal attorney of the Palo Alto Law firm, Longwell and Associates, which specializes in Food and Drug law. The firm has expertise in US FDA expectations, regulation and law, affecting the development and ultimate marketing of new medical products, drugs, devices and biologics. They have served the regulatory needs of large (>$2 billion/year) divisions of Fortune 500 companies, and small (4 person) biotech start-ups.
Contact Detail:
Compliance4All DBA NetZealous,
Phone: +1-800-447-9407
Email: support@compliance4All.com
http://www.compliance4all.com/
Event Link : http://bit.ly/510k_changes
LinkedIn Like us
Twitter Follow us
Facebook Like us
Source : Event Website
Attendees
Exhibitors
Register
| Event Name | City | State | Atendance | Exhibitors | Date |
|---|---|---|---|---|---|
| The Whole Bead Show January 2026 - Honolulu | Honolulu | Hawaii |  estimated |
estimated |
Jan 02, 2026 |
| TRENDZ Apparel Trade Show January 2026 | West Palm Beach | Florida | estimated |
estimated |
Jan 04, 2026 |
| TRENDZ WEST Apparel Trade Show February 2026 | West Palm Beach | Florida | estimated |
estimated |
Jan 04, 2026 |
| ASI Show Orlando 2026 - Advertising Specialty Institute | Orlando | Florida | estimated |
estimated |
Jan 05, 2026 |
| Association of Fund-Raising Distributors & Suppliers Conference & Expo 2026 - (formerly Association of Fundraising Distributors & Suppliers Expo) | Orlando | Florida | estimated |
estimated |
Jan 05, 2026 |
